Online inquiry

IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8742MR)

This product GTTS-WQ8742MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CCR5 gene. The antibody can be applied in AIDS, Graft-versus-host disease (GvHD) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000579.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1234
UniProt ID P51681
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ8742MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6660MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DMUC5754A
GTTS-WQ10742MR IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA M-6495
GTTS-WQ15042MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SRF-231
GTTS-WQ4037MR IVTScrip™ mRNA-Anti-IL23A, BI 655066(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BI 655066
GTTS-WQ6253MR IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CR-6261
GTTS-WQ6919MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ENB-0040
GTTS-WQ13196MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-04950615
GTTS-WQ3655MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BAY 1187982
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW